DermWire | Newest Articles Newest Articles en-us Wed, 22 Aug 2018 03:43:42 GMT Wed, 22 Aug 2018 03:43:42 GMT DermWire Report: Psoriasis in America in 2018 Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms -- and the mental emotional effects of those symptoms -- are overwhelming. The survey, "Psoriasis In America 2018," highlights diagnosis, treatment and quality of life of people with psoriasis, based on responses from 1,270 patients. Itching was the most common symptom (89 percent) and considered the mo… Tue, 21 Aug 2018 04:00:00 GMT MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasis MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from the US Phase 3 study. Results of the phase 3 study (n=796) show that MC2-01 Cream is superior to Taclonex Topical Suspension at Week 8 based on treatment success, defined as a minimum two-point decrease in the Physician Global Assessment (PGA) score (40.1% versus 24.0%, p < 0.0001). Accordin… Tue, 21 Aug 2018 04:00:00 GMT Whale of a Tale: Shark Gets Botox Injections It may sound fishy, but even sharks can benefit from Botox injections. Charles E. Crutchfield III, MD, and Crutchfield Dermatology in Eagan, MN recently assisted the veterinary staff at Minnesota Zoo in Apple Valley with a unique patient. Haps, a sand tiger shark, had developed scoliosis. Veterinarians in Australia reported that Botox has the potential to correct the spinal curvature in sharks. Earlier this month Dr. Crutchfield III (also a Clinical Professor of Dermatology at the Univer… Mon, 20 Aug 2018 04:00:00 GMT Melanoma Research Alliance Seeks Proposals, Funding Available The Melanoma Research Alliance (MRA) is soliciting proposals that address the gap in translational science (i.e., turning scientific discoveries into tools and/or treatments for high-risk individuals and melanoma patients). Successful proposals have the potential of applying important basic and preclinical discoveries to the near-term development of clinical trials and studies impacting melanoma detection, prevention, diagnosis, staging, and/or treatment. Proposals for clinical st… Mon, 20 Aug 2018 04:00:00 GMT Merix Pharmaceutical Corp: Releev Cold Sore Treatment Now in Convenience Stores Merix Pharmaceutical Corp’s Releev®1 Day Cold Sore Symptom Treatment is now available in convenience stores, including 7-Eleven and soon in Circle K in the United States. Releev 1 Day Cold Sore Symptom Treatment had already been available in drugstores like Walgreens, CVS, and Rite Aid. Releev contains Viracea a proprietary botanical extract formula. Merix says its patented Echinacea Extract with the FDA approved OTC antimicrobial antiseptic Benzalkonium Chloride is the fastest he… Mon, 20 Aug 2018 04:00:00 GMT "Phenomenal Gains" in Derm Device Market, Global Market Insights Predicts Dermatology devices market, an integral vertical of medical equipment space, of late, has been providing lucrative opportunities to the investors to exploit economies of scale. The claim is very well validated from the increasing attempts by the market giants to brainstorm innovative products that prove to be highly profitable for the consumers. However, the regulatory, tax, and financial issues associated with dermatology practices are some of the pivotal factors massively influencing the derma… Thu, 16 Aug 2018 04:00:00 GMT Ortho Dermatologics Resubmits NDA for Duobrii Lotion Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; IDP-118) lotion in the treatment of plaque psoriasis. "After meeting with the FDA and understanding the additional pharmacokinetic data required for Duobrii, we have resubmitted the NDA ahead of schedule," said Joseph C. Papa, chairman and CEO, Bausch Health. "We continue to have confidence in an appr… Thu, 16 Aug 2018 04:00:00 GMT Special to Practical Dermatology: ACS Chief Medical Officer Sounds Off On Sunscreen Misuse We are getting it all wrong when it comes to our reliance on sunscreen as the be all and end all protection from skin cancer, says Otis W. Brawley, MD, chief medical and scientific officer for the American Cancer Society in Atlanta. Sunscreen wasn’t developed so we could all get a free pass to spend the day on the beach. “Ultraviolet (UV) A rays cause melanoma and UV B causes sunburns, and most sunscreens block more B than A,” he says. This sets us up for melanoma. &ldqu… Wed, 15 Aug 2018 04:00:00 GMT Revision Skincare Launches DEJ Eye Cream, DEJ Face Cream Revision Skincare® has created two comprehensive products,DEJ eye cream® and DEJ face cream®, utilizing Pathway Technology and Prebiotic Innovation to provide clinically-proven results and promote long-term skin health, the company says. DEJ eye cream® addresses the appearance of dark circles and puffiness around the eye area, and is also uniquely formulated for the upper eyelid to improve the appearance of eyelid hooding, while also reducing the appearance of crow’s fee… Wed, 15 Aug 2018 04:00:00 GMT Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Market Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument's nitrous oxide and oxygen system, Nitronox™. Cynosure is the first medical aesthetic manufacturer to offer a nitrous oxide and oxygen system to its customers. Nitronox is a self-administered nitrous oxide and oxygen delivery system providing a fast-acting inhaled analgesic that h… Wed, 15 Aug 2018 04:00:00 GMT Burt’s Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimen Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a study in the Journal of Drugs in Dermatology. Burt’s Bees’ nature-based regimen consists of Sensitive Facial Cleanser, Sensitive Daily Moisturizing Cream and Sensitive Night Cream. This 4-week, double-blind, randomized study was conducted in 120 women with sensitive skin with clinically di… Tue, 14 Aug 2018 04:00:00 GMT Frequent BCC Linked to Other Cancers Basal cell carcinoma may increase risk for the development of other cancers, including blood, breast, colon and prostate cancers, according to a preliminary study by researchers at the Stanford University School of Medicine. "We discovered that people who develop six or more basal cell carcinomas during a 10-year period are about three times more likely than the general population to develop other, unrelated cancers," says Kavita Sarin, MD, PhD, assistant professor of dermatology, i… Mon, 13 Aug 2018 04:00:00 GMT Escalier Biosciences’ Doses First PsO Patient with ESR-114; Announces Clinical Advisory Board The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates our model of advancing high quality drug candidates from the bench to the clinic in less than two years," says Raju Mohan, Ph.D., founder and Chief Executive Officer of Escalier, in a news release. "We look forward to announcing top-line cli… Mon, 13 Aug 2018 04:00:00 GMT Pulse Biosciences: First Patient Treated in BCC Study The first patient has been treated in a clinical study to evaluate Nano-Pulse Stimulation (NPS) from Pulse Biosciences, Inc. for the treatment of Basal Cell Carcinoma (BCC). NPS is a non-thermal therapy that utilizes ultra-short, nanosecond pulsed electric fields that directly affect and disrupt intracellular structures and have been shown to induce immunogenic cell death in pre-clinical cancer models. Patients in the study will be treated with NPS prior to resection of the BCC lesion, which … Mon, 13 Aug 2018 04:00:00 GMT Neova Introduces Clinical Recovery Cream Neova SmartSkinCare is launching its Clinical Recovery range of products. The line of six new products is formulated to keep skin calm, soothed, hydrated, and protected following microdermabrasion, laser resurfacing, chemical peels,K and laser hair removal treatments for increased rates of healing, optimal skin recovery, significantly improved downtimes, and decreased risks of adverse side effects in post-procedure skin. Containing a revolutionary Copper Peptide Complex® based on more than 2… Fri, 10 Aug 2018 04:00:00 GMT Castle Creek Pharmaceuticals Gets FDA Fast Track Designation for Diacerein 1% Ointment for EBS The U.S. Food & Drug Administration (FDA) granted fast track status to Castle Creek Pharmaceuticals, LLC’s diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS). "Fast Track designation is an important milestone in our development program for CCP-020 and reinforces the critical unmet need for patients who are living with the risk of severe blistering and skin erosion associated with EBS," says Amir Tavakkol, PhD, executive vice president… Thu, 9 Aug 2018 04:00:00 GMT FDA Committee Recommends Approval of Paratek’s Omadacycline The Antimicrobials Drug Advisory Committee of the FDA voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) (17-1) and community-acquired bacterial pneumonia (CABP) (14-4). Paratek Pharmaceuticals, Inc.'s omadacycline is a modernized tetracycline being developed as a once-daily IV and oral, broad spectrum antibiotic for the treatment of serious community-acquired infections. “Omadacyc… Thu, 9 Aug 2018 04:00:00 GMT FDA Approves Poteligeo for Cutaneous T-Cell Lymphomas The FDA approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with two types of cutaneous T-cell lymphoma (CTCL) -- relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. “Mycosis fungoides and Sézary syndrome are rare, hard-to-treat types… Thu, 9 Aug 2018 04:00:00 GMT Ortho Dermatologics Names 2018 Aspire Higher Scholarship Recipients Ortho Dermatologics, a division of Bausch Health Companies Inc., has named the 2018 honorees of the Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students who have been affected by dermatologic conditions. This year nine students will receive scholarships of $10,000 each to pursue graduate or undergraduate degrees at an accredited, nonprofit, two- or four-year college, university, or advanced (post-high school) vocational or technical school. "… Wed, 8 Aug 2018 04:00:00 GMT Plastic Surgery Groups Issue Warning on the Risks of Brazilian Butt Lifts Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,” according to an American Society of Plastic Surgeons (ASPS) statement. “With the number of procedures doubling in the last five years, we believe it’s imperative to highlight the associated ri… Mon, 6 Aug 2018 04:00:00 GMT eRelevance Patient Engagement Survey Highlights Opportunities for Practices eRelevance Corporation, the leading provider of consumer engagement services for small- to medium-size businesses (SMBs) has released Patient Engagement for Growth: Aesthetic Practice Marketing Perspectives and Priorities. The report -- based on survey responses from nearly 150 US aesthetic practices -- examines the challenges and solutions related to patient engagement, and how practices can drive cash-based consumer demand while lowering advertising costs and improving marketing lead co… Fri, 3 Aug 2018 04:00:00 GMT Almirall to Acquire Allergan’s US Medical Dermatology Unit Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (fludroxycortide), as well as SeysaraTM (sarecycline), a new first in class tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of moderate to severe acne vulgaris, in … Fri, 3 Aug 2018 04:00:00 GMT Bonti’s Novel Neurotoxin Shines in Early Study of Scar Reduction After Mohs Surgery Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a faster onset of action (within 24 hours) and a shorter duration of activity (2 to 4 weeks) compared to botulinum neurotoxin serotype A (BoNT/A) products. In this trial, EB-001… Thu, 2 Aug 2018 04:00:00 GMT Dermatologist Named a Finalist for Inaugural FNIH Trailblazer Prize for Clinician-Scientists An oncodermatologist is in the running for the Foundation for the National Institutes of Health (FNIH) inaugural Trailblazer Prize for Clinician-Scientists. The three finalists are Daniel Bauer, MD, PhD, Harvard Medical School, Jaehyuk Choi, MD, PhD, Feinberg School of Medicine, Northwestern University and Michael Fox, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School. These three early-career clinician-scientists, whose work spans the fields of hematology, oncodermatology a… Wed, 1 Aug 2018 04:00:00 GMT Castle Biosciences’ DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence, Metastasis Castle Biosciences, Inc’s. DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging, according to a new study presented at the DERM2018 NP/PA CME Conference held in Las Vegas. The study assessed the impact on risk assessment for patients with Stage I-III melanoma when including results from the DecisionDx-Melanoma test along with population-based AJCC staging in a 690-patient cohort. The DecisionDx-Melanoma test … Wed, 1 Aug 2018 04:00:00 GMT